DSP Nifty Next 50 Index Fund An open ended scheme replicating / tracking NIFTY NEXT 50 Index |
Invests in 50 stocks beyond Nifty 50
The index aims to capture mega caps of tomorrow b catching them early in their growth cycle
Anil Ghelani
Total work experience of 21 years.
Managing this Scheme since
July 2019.
February 21, 2019
NIFTY Next 50 TRI
Regular Plan | |
Growth: | ₹ 09.2666 |
Direct Plan | |
Growth: | ₹ 09.3000 |
₹ 55 Cr
₹ 103 Cr
2.15
Regular Plan : | 0.59% |
Direct Plan : | 0.29% |
Nil
Name of Instrument | % to Net Assets |
EQUITY & EQUITY RELATED | |
Listed / awaiting listing on the stock exchanges | |
Finance | 25.85% |
✔ HDFC Life Insurance Company Limited | 4.49% |
✔ SBI Life Insurance Company Limited | 4.12% |
✔ ICICI Lombard General Insurance Company Limited | 3.95% |
ICICI Prudential Life Insurance Company Limited | 2.26% |
Shriram Transport Finance Company Limited | 2.01% |
Piramal Enterprises Limited | 1.81% |
Power Finance Corporation Limited | 1.70% |
HDFC Asset Management Company Limited | 1.65% |
Bajaj Holdings & Investment Limited | 1.60% |
Indiabulls Housing Finance Limited | 0.68% |
L&T Finance Holdings Limited | 0.62% |
General Insurance Corporation of India | 0.53% |
The New India Assurance Company Limited | 0.45% |
Consumer Non Durables | 20.08% |
✔ Dabur India Limited | 4.23% |
✔ Godrej Consumer Products Limited | 3.14% |
✔ Colgate Palmolive (India) Limited | 2.98% |
United Spirits Limited | 2.45% |
Marico Limited | 2.27% |
Berger Paints (I) Limited | 1.89% |
United Breweries Limited | 1.60% |
Procter & Gamble Hygiene and Health Care Limited | 1.52% |
Pharmaceuticals | 13.99% |
✔ Divi's Laboratories Limited | 4.55% |
✔ Lupin Limited | 3.07% |
Aurobindo Pharma Limited | 2.69% |
Biocon Limited | 2.41% |
Cadila Healthcare Limited | 1.27% |
Retailing | 5.44% |
✔ Avenue Supermarts Limited | 5.44% |
Chemicals | 3.56% |
✔ Pidilite Industries Limited | 3.56% |
Cement | 3.46% |
Ambuja Cements Limited | 1.93% |
ACC Limited | 1.53% |
Banks | 3.15% |
Bandhan Bank Limited | 1.68% |
Bank of Baroda | 0.90% |
Punjab National Bank | 0.57% |
Transportation | 3.03% |
Container Corporation of India Limited | 1.57% |
Interglobe Aviation Limited | 1.47% |
Auto Ancillaries | 3.00% |
Motherson Sumi Systems Limited | 1.61% |
Bosch Limited | 1.39% |
Gas | 2.79% |
Petronet LNG Limited | 2.79% |
Petroleum Products | 2.52% |
Hindustan Petroleum Corporation Limited | 2.52% |
Consumer Durables | 2.16% |
Havells India Limited | 2.16% |
Textile Products | 1.62% |
Page Industries Limited | 1.62% |
Industrial Capital Goods | 1.55% |
Siemens Limited | 1.55% |
Construction | 1.39% |
DLF Limited | 1.39% |
Auto | 1.15% |
Ashok Leyland Limited | 1.15% |
Minerals/Mining | 1.06% |
NMDC Limited | 1.06% |
Power | 0.87% |
Adani Transmission Limited | 0.87% |
Software | 0.83% |
Oracle Financial Services Software Limited | 0.83% |
Power | 0.74% |
NHPC Limited | 0.74% |
Non - Ferrous metals | 0.68% |
Hindustan Zinc Limited | 0.68% |
Telecom - Services | 0.46% |
Vodafone Idea Limited | 0.46% |
Total | 99.41% |
MONEY MARKET INSTRUMENTS | |
TREPS / Reverse Repo Investments / Corporate Debt Repo | 113.87% |
Total | 113.87% |
Cash & Cash Equivalent | |
Net Receivables/Payables | -113.28% |
Total | -113.28% |
GRAND TOTAL | 100.00% |
✔ Top Ten Holdings
Subject to SEBI (MF) Regulations and the applicable guidelines issued by SEBI, Scheme has entered into securities lending in accordance with the framework specified in this regard.
To invest in companies which are
constituents of NIFTY Next 50 Index
(underlying Index) in the same
proportion as in the index and
seeks to generate returns that are
commensurate (before fees and
expenses) with the performance
of the underlying Index, subject to
tracking error.
However, there is no assurance that the objective of the Scheme will be achieved. The Scheme does not assure or guarantee any returns.
This open ended equity Scheme is suitable for investors who are seeking*
• Long-term capital growth
• Returns that are commensurate with the performance of NIFTY Next 50 Index, subject to tracking
error.
* Investors should consult their financial advisors if in doubt whether the product is suitable for them.